Low-dose-intensity bevacizumab with weekly @entity2600 for XXXX - and @entity6023 -resistant @entity43 .

@entity1 @entity43 @entity137 @entity6023 @entity2600 @entity882 @entity101 @entity294 @entity1398 @entity299 @entity715 @entity902
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly @entity2600 as salvage treatment for @entity1 with @entity902 - and @entity6023 -resistant advanced @entity43 . METHODS: Fifty-two @entity1 with @entity902 - and @entity6023 -resistant advanced @entity43 received bevacizumab 5  mg/Kg days 1 and 15; @entity2600 60  mg/m(2) days 1, 8 and 15. The combined therapy was repeated every 28  days, up to six cycles. RESULTS: A total of 230 cycles of bevacizumab combined with @entity2600 were administrated to 52 @entity1 . Among the 52 @entity1 , 22 @entity1 achieved partial response (42.3  %); 12 @entity1 had stable disease (23.1  %) and 18 @entity1 experienced disease progression (34.6  %). The median progression-free survival and the median overall survival were 8.0  months (95  % confidence interval: 6.74-9.26  months) and 13.8  months (95  % confidence interval: 11.97-15.63  months), respectively. The most frequent grade 3-4 hematologic @entity137 were @entity1398 (11.5  %) and @entity882 (3.8  %). The non-hematologic @entity137 included grade 3 @entity294 (3.8  %) and @entity101 (3.8  %). Two @entity1 (3.8  %) were confirmed with deep vein @entity715 . @entity1398 , symptomatic @entity299 and gastrointestinal perforation were not observed in this study. CONCLUSIONS: The combination of low-dose-intensity bevacizumab and weekly @entity2600 was an effective and safe regimen for @entity1 with @entity902 - and @entity6023 -resistant @entity43 .
